Bellevue reports 6.8% stake in Jade Biosciences
Bellevue Group AG, through its wholly owned subsidiary Bellevue Asset Management AG, reported a significant passive ownership stake in Jade Biosciences, Inc. common stock.
Rhea-AI Filing Summary
Bellevue Group AG, through its wholly owned subsidiary Bellevue Asset Management AG, reported a significant passive ownership stake in Jade Biosciences, Inc. common stock. They beneficially own 3,341,103 shares, representing 6.8% of the outstanding common stock, with shared voting and dispositive power over all of these shares.
The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Jade Biosciences. Bellevue and its subsidiary certify that the information provided is true, complete, and correct.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in JBIO does Bellevue Group report on this Schedule 13G?
Is Bellevue Group’s stake in Jade Biosciences (JBIO) a passive investment?
Who are the reporting persons on the Jade Biosciences (JBIO) Schedule 13G?
What regulatory status does Bellevue Asset Management claim in this JBIO filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.